Filing Flows › Viridian Therapeutics (VRDN) › Q2 2026 › vs Q1 2026
Viridian Therapeutics (VRDN) Q2 2026 vs Q1 2026 (quarter over quarter)
Viridian Therapeutics's revenue rose $143K (+101%) from $141K in Q1 2026 to $284K in Q2 2026.
Viridian Therapeutics, Q2 2026: revenue $284K (+279% year over year), net loss $127M, operating cash flow −$105M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $284K | $141K | $143K | +101% |
| Net loss | $127M | $105M | $22.2M | +21% |
| Costs & expenses | $127M | $116M | $11.1M | +10% |
| Operating costs | $127M | $116M | $10.2M | +9% |
| Interest & other, net | $851K | −$11.3M | $12.1M | — |
| Research & development | $71.6M | $77.6M | −$6.1M | -8% |
| SG&A | $55.0M | $38.7M | $16.3M | +42% |
| Operating cash sources | $127M | $105M | $22.2M | +21% |
| Depreciation & amortization | $117K | $121K | −$4K | -3% |
| Share-based compensation | $17.0M | $13.4M | $3.6M | +27% |
| Working capital & other | $4.7M | −$28.3M | $33.0M | — |
| Cash used in operations | $105M | $120M | −$14.3M | -12% |
| Net loss absorbed | $127M | $105M | $22.2M | +21% |
Questions
How much did Viridian Therapeutics's revenue grow quarter over quarter in Q2 2026?
Viridian Therapeutics's revenue rose $143K (+101%) from $141K in Q1 2026 to $284K in Q2 2026.